{"id":"NCT02728089","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)","officialTitle":"A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) in Japanese Patients With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-14","primaryCompletion":"2017-09-05","completion":"2017-09-05","firstPosted":"2016-04-05","resultsPosted":"2018-09-19","lastUpdate":"2019-02-05"},"enrollment":115,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Tract Infection (UTI)","Complicated Urinary Tract Infection","Pyelonephritis","Uncomplicated Pyelonephritis"],"interventions":[{"type":"DRUG","name":"MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)","otherNames":[]}],"arms":[{"label":"MK-7625A","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, multi-site, non-randomized, open-label study evaluating the safety and efficacy of MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) for the treatment of complicated urinary tract infection (cUTI) including pyelonephritis (uncomplicated or complicated pyelonephritis and complicated lower urinary tract infection) in Japanese participants. Efficacy will be primarily assessed by microbiological response defined as eradication of the baseline pathogen or pathogens.","primaryOutcome":{"measure":"Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC)","timeFrame":"Day 14 (14 days post first dose of study drug)","effectByArm":[{"arm":"MK-7625A","deltaMin":80.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":20},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["30420153"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":114},"commonTop":["Constipation","Diarrhoea","Alanine aminotransferase increased","Aspartate aminotransferase increased"]}}